- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/69 - Two or more oxygen atoms
Patent holdings for IPC class C07D 213/69
Total number of patents in this class: 355
10-year publication summary
|
34
|
25
|
35
|
39
|
25
|
21
|
25
|
15
|
12
|
9
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Sumitomo Chemical Company, Limited | 9047 |
20 |
| Takeda Pharmaceutical Company Limited | 2705 |
13 |
| Bristol-myers Squibb Company | 4867 |
11 |
| Bayer Pharma AG | 1054 |
9 |
| Global Blood Therapeutics, Inc. | 183 |
9 |
| Nimmune Biopharma, Inc. | 25 |
7 |
| Selling Entities | 14 |
7 |
| Novartis AG | 10730 |
6 |
| Genentech, Inc. | 3994 |
6 |
| Shionogi & Co., Ltd. | 849 |
6 |
| Boehringer Ingelheim International GmbH | 4642 |
5 |
| Glaxosmithkline Intellectual Property Development Limited | 764 |
5 |
| Vertex Pharmaceuticals Incorporated | 1623 |
5 |
| Celgene Quanticel Research, Inc. | 163 |
5 |
| Liminal Biosciences Limited | 24 |
5 |
| Merck Sharp & Dohme LLC | 3760 |
5 |
| BASF SE | 20979 |
4 |
| Pfizer Inc. | 3368 |
4 |
| Syngenta Participations AG | 1847 |
4 |
| Apotex Inc. | 204 |
4 |
| Other owners | 215 |